|
SG10201912038TA
(en)
|
2014-04-23 |
2020-02-27 |
Modernatx Inc |
Nucleic acid vaccines
|
|
WO2017020026A1
(en)
|
2015-07-30 |
2017-02-02 |
Modernatx, Inc. |
Concatemeric peptide epitopes rnas
|
|
WO2017031232A1
(en)
|
2015-08-17 |
2017-02-23 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
|
EP3364981A4
(en)
|
2015-10-22 |
2019-08-07 |
ModernaTX, Inc. |
VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
|
|
EP3364949A4
(en)
|
2015-10-22 |
2019-07-31 |
ModernaTX, Inc. |
CANCER VACCINES
|
|
TW201729835A
(zh)
|
2015-10-22 |
2017-09-01 |
現代公司 |
呼吸道病毒疫苗
|
|
HRP20220652T1
(hr)
|
2015-12-10 |
2022-06-24 |
Modernatx, Inc. |
Pripravci i postupci unosa terapijskih sredstava
|
|
MA45052A
(fr)
|
2016-05-18 |
2019-03-27 |
Modernatx Inc |
Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille
|
|
CN116837052A
(zh)
|
2016-09-14 |
2023-10-03 |
摩登纳特斯有限公司 |
高纯度rna组合物及其制备方法
|
|
MA46584A
(fr)
|
2016-10-21 |
2019-08-28 |
Modernatx Inc |
Vaccin contre le cytomégalovirus humain
|
|
WO2018089851A2
(en)
|
2016-11-11 |
2018-05-17 |
Modernatx, Inc. |
Influenza vaccine
|
|
US11045540B2
(en)
|
2017-03-15 |
2021-06-29 |
Modernatx, Inc. |
Varicella zoster virus (VZV) vaccine
|
|
US11752206B2
(en)
|
2017-03-15 |
2023-09-12 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
|
EP3595713A4
(en)
|
2017-03-15 |
2021-01-13 |
ModernaTX, Inc. |
RESPIRATORY SYNCYTIAL VIRUS Vaccine
|
|
WO2018170245A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
MA47790A
(fr)
|
2017-03-17 |
2021-05-05 |
Modernatx Inc |
Vaccins à base d'arn contre des maladies zoonotiques
|
|
WO2018187590A1
(en)
|
2017-04-05 |
2018-10-11 |
Modernatx, Inc. |
Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
|
|
US11786607B2
(en)
|
2017-06-15 |
2023-10-17 |
Modernatx, Inc. |
RNA formulations
|
|
WO2019036683A1
(en)
|
2017-08-18 |
2019-02-21 |
Modernatx, Inc. |
ANALYTICAL METHODS BY HPLC
|
|
WO2019036685A1
(en)
|
2017-08-18 |
2019-02-21 |
Modernatx, Inc. |
METHODS FOR HPLC ANALYSIS
|
|
ES2983060T3
(es)
|
2017-08-18 |
2024-10-21 |
Modernatx Inc |
Variantes de ARN polimerasa
|
|
WO2019046809A1
(en)
|
2017-08-31 |
2019-03-07 |
Modernatx, Inc. |
METHODS OF MANUFACTURING LIPID NANOPARTICLES
|
|
WO2019148101A1
(en)
|
2018-01-29 |
2019-08-01 |
Modernatx, Inc. |
Rsv rna vaccines
|
|
AU2019345067A1
(en)
|
2018-09-19 |
2021-04-08 |
Modernatx, Inc. |
High-purity peg lipids and uses thereof
|
|
MA53650A
(fr)
|
2018-09-19 |
2021-07-28 |
Modernatx Inc |
Lipides peg et leurs utilisations
|
|
CN113271926A
(zh)
|
2018-09-20 |
2021-08-17 |
摩登纳特斯有限公司 |
脂质纳米颗粒的制备及其施用方法
|
|
CN113795579A
(zh)
|
2019-02-20 |
2021-12-14 |
摩登纳特斯有限公司 |
用于共转录加帽的rna聚合酶变体
|
|
US11851694B1
(en)
|
2019-02-20 |
2023-12-26 |
Modernatx, Inc. |
High fidelity in vitro transcription
|
|
CA3132975A1
(en)
|
2019-03-11 |
2020-09-17 |
Modernatx, Inc. |
Fed-batch in vitro transcription process
|
|
EP3938379A4
(en)
|
2019-03-15 |
2023-02-22 |
ModernaTX, Inc. |
Hiv rna vaccines
|
|
US12194089B2
(en)
|
2020-02-04 |
2025-01-14 |
CureVac SE |
Coronavirus vaccine
|
|
US11241493B2
(en)
|
2020-02-04 |
2022-02-08 |
Curevac Ag |
Coronavirus vaccine
|
|
EP3901261A1
(en)
|
2020-04-22 |
2021-10-27 |
BioNTech RNA Pharmaceuticals GmbH |
Coronavirus vaccine
|
|
JP2023525936A
(ja)
*
|
2020-05-18 |
2023-06-19 |
康希諾（上海）生物科技有限公司 |
ｍＲＮＡ又はｍＲＮＡ組成物、その調製方法及び使用
|
|
AU2021294342A1
(en)
*
|
2020-06-26 |
2023-02-23 |
Elicio Therapeutics, Inc. |
Compositions and methods for inducing an immune response against coronavirus
|
|
WO2022046583A1
(en)
*
|
2020-08-24 |
2022-03-03 |
Phylex Biosciences, Inc. |
Reagents and methods for preventing, treating or limiting severe acute respiratory syndrome (sars) coronavirus infection
|
|
US11406703B2
(en)
|
2020-08-25 |
2022-08-09 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
US20220193225A1
(en)
*
|
2020-08-31 |
2022-06-23 |
Bruce Lyday |
Compositions and methods for sars-2 vaccine with virus replicative particles and recombinant glycoproteins
|
|
US20230416309A1
(en)
*
|
2020-10-23 |
2023-12-28 |
Jiangsu Provincial Center For Disease Control And Prevention (Public Health Research Institute Of Ji |
Fusion protein and application thereof
|
|
CN114517205A
(zh)
*
|
2020-11-20 |
2022-05-20 |
北京震旦鼎泰生物科技有限公司 |
融合基因及一种重组新型冠状病毒高效免疫鼎分子dna疫苗及其构建方法和应用
|
|
US20240156946A1
(en)
|
2020-12-22 |
2024-05-16 |
CureVac SE |
Rna vaccine against sars-cov-2 variants
|
|
US12329811B2
(en)
|
2021-01-11 |
2025-06-17 |
Modernatx, Inc. |
Seasonal RNA influenza virus vaccines
|
|
EP4277655A1
(en)
*
|
2021-01-15 |
2023-11-22 |
ModernaTX, Inc. |
Variant strain-based coronavirus vaccines
|
|
US11524023B2
(en)
*
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
|
EP4308156A1
(en)
*
|
2021-03-15 |
2024-01-24 |
ModernaTX, Inc. |
Therapeutic use of sars-cov-2 mrna domain vaccines
|
|
WO2022215036A1
(en)
|
2021-04-08 |
2022-10-13 |
Vaxthera Sas |
Coronavirus vaccine comprising a mosaic protein
|
|
US20240321387A1
(en)
|
2021-05-04 |
2024-09-26 |
BioNTech SE |
Immunogen selection
|
|
US20220363937A1
(en)
|
2021-05-14 |
2022-11-17 |
Armstrong World Industries, Inc. |
Stabilization of antimicrobial coatings
|
|
EP4384212A4
(en)
*
|
2021-08-15 |
2025-06-25 |
Dennis R. Burton |
Undirected mutated mrna vaccine
|
|
EP4387592A4
(en)
*
|
2021-08-17 |
2025-08-06 |
Univ Monash |
VACCINE COMPOSITIONS
|
|
AU2022333308A1
(en)
*
|
2021-08-24 |
2024-03-07 |
Victoria Link Limited |
Fusion polypeptide
|
|
WO2023034991A1
(en)
*
|
2021-09-02 |
2023-03-09 |
Kansas State University Research Foundation |
Mrna vaccine formulations and methods of using the same
|
|
CN113527522B
(zh)
*
|
2021-09-13 |
2021-12-21 |
深圳市瑞吉生物科技有限公司 |
一种新冠病毒三聚体重组蛋白、DNA、mRNA及应用和mRNA疫苗
|
|
CN116064598B
(zh)
*
|
2021-10-08 |
2024-03-12 |
苏州艾博生物科技有限公司 |
冠状病毒的核酸疫苗
|
|
WO2023060483A1
(zh)
*
|
2021-10-13 |
2023-04-20 |
清华大学 |
多肽-rbd免疫偶联物及其用途
|
|
CN118302189A
(zh)
|
2021-10-21 |
2024-07-05 |
生物技术欧洲股份公司 |
冠状病毒疫苗
|
|
US20250026793A1
(en)
*
|
2021-10-21 |
2025-01-23 |
The University Of Melbourne |
Chimeric betacoronavirus spike polypeptides
|
|
WO2023092069A1
(en)
*
|
2021-11-18 |
2023-05-25 |
Modernatx, Inc. |
Sars-cov-2 mrna domain vaccines and methods of use
|
|
EP4436984A1
(en)
*
|
2021-11-24 |
2024-10-02 |
Flagship Pioneering Innovations VI, LLC |
Coronavirus immunogen compositions and their uses
|
|
US12186387B2
(en)
|
2021-11-29 |
2025-01-07 |
BioNTech SE |
Coronavirus vaccine
|
|
TW202333780A
(zh)
|
2021-11-29 |
2023-09-01 |
德商拜恩技術股份公司 |
冠狀病毒疫苗
|
|
IL288634A
(en)
*
|
2021-12-02 |
2023-07-01 |
Yeda Res & Dev |
Improving the translation and protein secretion efficiency of mRNA vaccines
|
|
WO2023113094A1
(ko)
*
|
2021-12-16 |
2023-06-22 |
주식회사 씨티씨백 |
면역원성이 증가된 코로나바이러스감염증-19 백신 조성물
|
|
US12529047B1
(en)
|
2021-12-21 |
2026-01-20 |
Modernatx, Inc. |
mRNA quantification methods
|
|
CN116376942A
(zh)
*
|
2021-12-31 |
2023-07-04 |
广州国家实验室 |
mRNA疫苗
|
|
WO2023142283A1
(zh)
|
2022-01-27 |
2023-08-03 |
深圳市瑞吉生物科技有限公司 |
一种新型冠状病毒mRNA疫苗及其制备方法与应用
|
|
EP4242308A1
(en)
|
2022-01-27 |
2023-09-13 |
Shenzhen Rhegen Biotechnology Co., Ltd. |
Sars-cov-2 mrna vaccine, and preparation method therefor and use thereof
|
|
WO2023143600A1
(zh)
*
|
2022-01-30 |
2023-08-03 |
康希诺生物股份公司 |
一种用于核酸递送的新型可电离脂质及其lnp组合物和疫苗
|
|
CN116554042A
(zh)
*
|
2022-01-30 |
2023-08-08 |
康希诺生物股份公司 |
一种用于核酸递送的新型可电离脂质及其lnp组合物和疫苗
|
|
CN114213509B
(zh)
*
|
2022-02-22 |
2022-06-10 |
广州市锐博生物科技有限公司 |
基于SARS-CoV-2的S蛋白的疫苗及其用途
|
|
CN116726162A
(zh)
*
|
2022-03-11 |
2023-09-12 |
病毒与疫苗研究中心有限公司 |
用于呼吸道病毒性疾病的疫苗加强组合物
|
|
KR102850225B1
(ko)
*
|
2022-04-07 |
2025-09-18 |
엠큐렉스 주식회사 |
사스-코로나바이러스 2 감염증에 대한 rna 백신
|
|
WO2024002985A1
(en)
|
2022-06-26 |
2024-01-04 |
BioNTech SE |
Coronavirus vaccine
|
|
EP4604995A1
(en)
|
2022-10-17 |
2025-08-27 |
BioNTech SE |
Combination vaccines against coronavirus infection, influenza infection, and/or rsv infection
|
|
WO2024089638A1
(en)
|
2022-10-28 |
2024-05-02 |
Glaxosmithkline Biologicals Sa |
Nucleic acid based vaccine
|
|
CN115960923A
(zh)
*
|
2022-11-24 |
2023-04-14 |
威瑞生物科技(昆明)有限责任公司 |
一种包含非人种属调控元件的SARS-COV-2刺突蛋白mRNA及其构建方法与应用
|
|
WO2024141784A2
(en)
*
|
2022-12-29 |
2024-07-04 |
Popvax Private Limited |
Broadly protective betacoronavirus vaccines and compositions
|
|
CN120435314A
(zh)
*
|
2022-12-29 |
2025-08-05 |
波普瓦克斯私人有限公司 |
多靶疫苗和治疗剂
|
|
IL322194A
(en)
*
|
2023-01-20 |
2025-09-01 |
Astrazeneca Ab |
Nucleic acid molecules
|
|
CN117003835A
(zh)
*
|
2023-03-17 |
2023-11-07 |
成都威斯克生物医药有限公司 |
抗SARS-CoV-2奥密克戎突变株XBB及其亚型感染的蛋白及疫苗
|
|
WO2025027492A1
(en)
*
|
2023-07-31 |
2025-02-06 |
Pfizer Inc. |
Coronavirus antigen variants
|
|
GB202416789D0
(en)
*
|
2023-11-15 |
2025-01-01 |
BioNTech SE |
SARS-COV-2 immunogenic compositions
|
|
WO2025106754A1
(en)
|
2023-11-15 |
2025-05-22 |
BioNTech SE |
Coronavirus vaccine
|
|
WO2026047603A1
(en)
*
|
2024-08-28 |
2026-03-05 |
BioNTech SE |
Sars-cov-2 immunogenic compositions
|